Enveric Biosciences Advances EB-003 for Mental Health Disorders, Reports FY 2025 Financial Results

Enveric Biosciences reported financial results and provided a corporate update for Q4 and FY 2025. The company's CEO, Joseph Tucker, highlighted the progress of its lead candidate, EB-003, a non-hallucinogenic neuroplastogen for treating mental health conditions. Enveric is preparing for an IND application to the FDA and plans to initiate a Phase 1 clinical trial in 2026. The company's patent portfolio was also defended against a Post-Grant Review petition filed by AbbVie.